Claybrook Capital’s Emergent Biosolutions EBS Stock Holding History

Claybrook Capital’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-73	Closed	-$4K	–	245
2018 Q4	$4K	Buy	+73	New	+$4.71K	﹤0.01%	589

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Claybrook Capital's EBS Position: Q1 2019 in Review

Claybrook Capital sold out of Emergent Biosolutions (EBS) in Q1 2019, closing a stake of 73 shares — an estimated $4K sold.

Claybrook Capital first reported a position in EBS in Q4 2018 and held it in 1 quarter. The position peaked at $4K in Q4 2018. 272 funds tracked by Wall St. Rank hold EBS as of Q1 2019.

Claybrook Capital reported no remaining Emergent Biosolutions position as of Q1 2019 after selling out during the quarter.
Claybrook Capital sold 73 Emergent Biosolutions shares in Q1 2019, an estimated $4K.
Claybrook Capital first reported a position in Emergent Biosolutions in Q4 2018 and held it in 1 quarter.
Claybrook Capital's Emergent Biosolutions position peaked at $4K in Q4 2018.
272 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2019.

Based on Claybrook Capital's 13F filing for Q1 2019, filed 15 May 2019.